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Optimal oral drug dosing via application of the
Contraction Mapping Theorem
Neil D. Evansa
aSchool of Engineering, University of Warwick, Coventry, CV4 7AL, UK
Abstract
The problem of determining an oral dose, or schedule of oral doses, that gives
rise to an arbitrary area-under-curve or to points on the time-series for a vari-
able of interest in a drug kinetics model is considered. These two measures
are considered as surrogates for the particular drug response to the dose. The
approach taken is to formulate the problem as a ﬁxed point one to which a
version of the Contraction Mapping Theorem can be applied. The results,
illustrated for a model for the anti-cancer agent topotecan, demonstrate the
applicability of the approach.
Keywords: Optimization problems, Biomedical control, Biomedical
systems, Control applications, Control algorithms
1. Introduction1
One of the beneﬁts of a drug kinetics model is that it permits the pre-2
diction of the eﬀect of a given dose on the kinetics of the drug, such as3
its absorption, distribution, metabolism and elimination. Typically one, or4
some combination, of the model variables corresponds to pharmacological5
activity and this might be linked to the drug dynamics, in terms of the ef-6
fect of the drug. Perhaps the simplest kinetic model is a one-compartment7
(variable) model describing the plasma concentration of drug with linear8
elimination, which gives rise to a decaying exponential time course following9
a bolus injection of drug. Properties of the time course, such as half-life or10
area-under-curve, might be indicators or predictors of the eﬃcacy of the drug11
dose.12
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For example, Evans et al. [1] propose a model for the in vitro uptake13
kinetics of the anti-cancer agent topotecan (TPT). TPT, a water-soluble14
semi-synthetic derivative of camptothecin [2], is a reversible poison of the15
nuclear enzyme topoisomerase I [3], which is an enzyme used to alleviate16
torsional stresses during DNA replication [4]. The drug exists in two forms,17
a pharmacologically active parent lactone form (TPT-L), and an inactive18
hydroxy acid form (TPT-H). The model proposed in [1] describes the kinetics19
of the two forms of TPT from input into the medium to delivery to the20
DNA target, which is represented by a variable in the model corresponding21
to TPT-L bound to nuclear DNA. The area under the concentration-time22
curve (AUC) for this variable is used as a surrogate for the ‘hit-on-target’,23
that is, the eﬀectiveness of the drug dose. More recently, Chappell et al.24
[5] coupled the kinetic model with a cell cycle dynamics model in which the25
concentration-time curve is used directly to consider eﬀectiveness of the drug26
dose. In this case it is the full time series proﬁle of TPT-L bound to DNA27
that is important in determining the eﬀect of the drug.28
In this paper the problem of determining an optimal oral dose, or oral dos-29
ing schedule, for a drug kinetics model is considered. Optimality is regarded30
with respect to either hit-on-target as represented by the AUC for a partic-31
ular times-series, or to achieving pre-deﬁned points on a given time-series.32
The approach taken is to reformulate the problem in such a way as to make33
the solution the ﬁxed point of a suitable contraction mapping. The approach34
taken is based on that taken by Evans and Pritchard [6] for containing the35
outbreak of rabies in a previously naive population.36
The earliest use of ﬁxed point methods in a control context was by Her-37
mes [7] for ﬁnite-dimensional systems. Davison and Kunze [8] describe the38
application of ﬁxed point methods to ﬁnite-dimensional time-varying sys-39
tems, and this approach has been extended to inﬁnite-dimensional systems40
by Magnusson and Pritchard [9]. Carmichael and Quinn [10] provide an early41
review of the use of ﬁxed point methods in nonlinear control and observation.42
The following version of the Contraction Mapping Theorem from [11] is43
used in this paper:44
Theorem 1. Suppose that 휑 : 푊 −→ 푊 is a mapping between Banach45
spaces that satisﬁes46
∥휑푥− 휑푦∥ ≤ 푘∥푥− 푦∥, 0 ≤ 푘 < 1
2
(푘 a constant), for 푥, 푦 ∈ 퐷, a subset of 푊 . If both the ball47
푆 =
{
푤 ∈ 푊 : ∥푤 − 푤1∥ ≤ 푘
1− 푘∥푤1 − 푤0∥
}
and 푤0 lie in 퐷, then the iterative process 푤푖+1 = 휑푤푖 converges to a unique48
ﬁxed-point in 퐷.49
2. Arbitrary area-under-curve50
Consider the problem of choosing a drug dose 푑 for a general drug kinetic51
model of the following form:52
푧˙(푡) = 푓(푧(푡)), 푧(0) = 푧0 + 퐵푑 (1)
푦(푡) = 퐶푧(푡) (2)
such that a particular area-under-curve (AUC) value is obtained for the de-53
sired time course 푦(푡). Thus the problem is to choose 푑 such that 푦푇 =54 ∫ 푇
0
푦(푡) d푡 = 푦d, for some target value, 푦d.55
Suppose that an initial guess is made for the dose, 푑 = 푑ˆ, which gives rise56
to the following AUC value:57
푦ˆ푇 =
∫ 푇
0
퐶푧ˆ(푡) d푡
where 푧ˆ(푡) is the solution of the initial value problem58
˙ˆ푧(푡) = 푓(푧ˆ(푡)), 푧ˆ(0) = 푧0 + 퐵푑ˆ.
Since this is unlikely to yield the desired value consider perturbations from59
this solution; that is, set 푥(푡) = 푧(푡)− 푧ˆ(푡) and 푢 = 푑− 푑ˆ in Equation (1) to60
yield the following:61
푥˙(푡) = 푓(푥(푡) + 푧ˆ(푡))− 푓(푧ˆ(푡)) = 퐴(푡)푥(푡) +푁(푡, 푥(푡)), 푥(0) = 퐵푢
where 퐴(푡) is the Jacobian matrix of 푓 (with respect to 푧) evaluated at 푧ˆ(푡).62
With respect to this perturbed system the output of interest becomes:63
푦푇 = 퐶
∫ 푇
0
(푥(푡) + 푧ˆ(푡)) d푡 = 퐶
∫ 푇
0
푥(푡) d푡+ 푦ˆ푇 .
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Neglecting (for now) the nonlinearity, the problem corresponds to choosing64
푢 such that:65
퐶
∫ 푇
0
휙(푠, 0)퐵푢 d푠 = 푚푇푢 = 푦d − 푦ˆ푇 where 푚푇 = 퐶
∫ 푇
0
휙(푠, 0)퐵 d푠
and 휙(⋅, ⋅) is the state-transition matrix for the time-varying linear system.66
Since 푚푇 is a number then the unique solution (for the linear system) is67
given by:68
푢∗ = (푦d − 푦ˆ푇 ) /푚푇 .
Now considering the full nonlinear system this suggests choosing 푢 such that:69
퐶
∫ 푇
0
푥(푡) d푡 = 퐶
∫ 푇
0
[
휙(푡, 0)퐵푢+
∫ 푡
0
휙(푡, 푠)푁(푠, 푥(푠))d푠
]
d푡
= 푦d − 푦ˆ푇 ,
giving70
푚푇푢 = 푦d − 푦ˆ푇 − 퐶
∫ 푇
0
∫ 푡
0
휙(푡, 푠)푁(푠, 푥(푠)) d푠 d푡
and so the choice for the dose is given by71
푢∗ =
1
푚푇
[
푦d − 푦ˆ푇 − 퐶
∫ 푇
0
∫ 푡
0
휙(푡, 푠)푁(푠, 푥(푠)) d푠 d푡
]
. (3)
This, however, gives an implicit relationship between 푢∗ and the solution 푥
(which requires 푢∗). To overcome this problem a ﬁxed-point is sought of the
following operator:
(Ψ푥) (푡) =
∫ 푡
0
휙(푡, 푠)푁(푠, 푥(푠)) d푠
+푚−1푇 휙(푡, 0)퐵
[
푦d − 푦ˆ푇 − 퐶
∫ 푇
0
∫ 푡
0
휙(푡, 푠)푁(푠, 푥(푠)) d푠 d푡
]
. (4)
If 푥 is a ﬁxed point of this operator, Ψ, then the AUC for the dose 푑ˆ+ 푢∗ is72
then given by:73
푦푇 = 퐶
∫ 푇
0
푥(푡) d푡+ 푦ˆ푇 = 퐶
∫ 푇
0
(Ψ푥) (푡) d푡+ 푦ˆ푇 = 푦d.
Thus the desired AUC is achieved for the dose 푑ˆ+ 푢∗, provided there exists74
a ﬁxed point of the operator Ψ deﬁned in (4).75
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Theorem 2. Suppose that the following are satisﬁed:76
1. 푁(⋅, 푥(⋅)) ∈ 퐿푠(0, 푇 ;ℝ푛) whenever 푥(⋅) ∈ 퐿푟(0, 푇 ;ℝ푛) where 푟, 푠 ≥ 177
are real numbers;78
2. 푁 : [0, 푇 ] × ℝ푛 −→ ℝ푛 is Lipschitz on the ball 퐵(푎) of radius 푎 about79
the origin in 퐿푟(0, 푇 ;ℝ푛):80
∥푁(⋅, 푧1(⋅))−푁(⋅, 푧2(⋅))∥푠 ≤ ℎ(∥푧1∥, ∥푧2∥)∥푧1 − 푧2∥푟
for 푧푖 ∈ 퐵(푎) and ℎ : ℝ+ × ℝ+ → ℝ+ is continuous, symmetric and81
ℎ(0, 0) = 0;82
3. Let 푎 ≤ 푎 be such that83
∥휙∥
[
푇∥휙∥ ∥퐵∥ ∥퐶∥
∣푚푇 ∣ + 1
]
푇˜퐾 = 퐾˜ < 1
where 퐾 = sup0≤푤,푣≤푎 ℎ(푤, 푣) and 푇˜ = 푇
(1+ 1
푟
− 1
푠
).84
If the AUC corresponding to the initial dose, 푦ˆ푇 , is close to the target value85
in the sense that86
∥푦d − 푦ˆ푇∥ ≤
푎∣푚푇 ∣
(
1− 퐾˜
)
∥휙∥푇 1/푟∥퐵∥ (5)
then the operator Ψ in Equation (4) has a unique ﬁxed point.87
Proof. To see that Ψ is a contraction on the ball 퐵(푎) note that:
∥Ψ푥1 −Ψ푥2∥푟 ≤ 푇˜∥휙∥퐾∥푥1 − 푥2∥푟 + 푇 푇˜ ∣푚푇 ∣−1 ∥휙∥2∥퐵∥ ∥퐶∥퐾∥푥1 − 푥2∥푟
= ∥휙∥
[
푇∥휙∥ ∥퐵∥ ∥퐶∥
∣푚푇 ∣ + 1
]
푇˜퐾∥푥1 − 푥2∥푟.
Let 푥0 = 0, 푥1 = Ψ푥0 = 푚
−1
푇 휙(⋅, 0)퐵 [푦d − 푦ˆ푇 ] and 푆 be the ball88
푆 =
{
푥 ∈ 퐿푟(0, 푇 ;ℝ푛) : ∥푥− 푥1∥ ≤ 퐾˜
1− 퐾˜ ∥푥1∥푟
}
.
푆 is contained within the ball 퐵(푎) provided89 [
1 +
퐾˜
1− 퐾˜
]
∥푚−1푇 휙(⋅, 0)퐵 [푦d − 푦ˆ푇 ] ∥푟 ≤ 푎
which is guaranteed by Equation (5). Applying Theorem 1 proves the re-90
quired result.91
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A natural extension to the problem considered in this section is to consider92
multiple doses. However, since it is possible to achieve any desired AUC for93
a single dose it seems natural to consider the problem of achieving diﬀerent94
AUC values on diﬀerent time intervals. This problem reduces to repeated95
application of the single dose problem above.96
3. Reference time-series97
Now consider the problem, for (1)–(2), of choosing a dose, or sequence of98
doses, such that particular points on the times series curve for 푦 are achieved.99
Therefore, let 푌d =
(
푦r(푡1) 푦r(푡2) . . . 푦r(푡푚)
)푇
denote a vector of points100
on a desired time-series curve 푦r. The control problem is to achieve these101
points for a suitable dose 푑, or doses 푑푖.102
Consider the problem with 푙 doses at regular intervals of 푇 starting at103
푡 = 0:104
푧˙푖(푡) = 푓(푧푖(푡)), 푧푖(0) = 푧푖−1(푇 ) + 퐵푑푖 (6)
푦푖(푡) = 퐶푧푖(푡) (7)
푌푖 =
(
푦푖(푡1푖) . . . 푦푖(푡푚푖)
)푇
(8)
where 푧1(0) = 푧0 + 퐵푑1 and 푖 = 1, . . . , 푙.105
Proceeding in a similar manner as in the previous section, let 푑ˆ푖 denote106
initial guesses for the doses, which give rise to output time series of the form:107
푦ˆ푖(푡) = 퐶푧ˆ푖(푡) and 푌ˆ푖 =
(
푦ˆ푖(푡1푖) 푦ˆ푖(푡2푖) . . . 푦ˆ푖(푡푚푖)
)푇
where 푧ˆ푖(푡) is the solution of the initial value problem given by (6)–(7) with108
푑ˆ푖 replacing 푑푖. Again, let 푥푖(푡) = 푧푖(푡)− 푧ˆ푖(푡) and 푢푖 = 푑푖 − 푑ˆ푖 in (6)–(8) to109
yield the following:110
푥˙푖(푡) = 퐴푖(푡)푥푖(푡) +푁푖(푡, 푥푖(푡)), 푥푖(0) = 푥푖−1(푇 ) + 퐵푢푖
where 퐴푖(푡) is the Jacobian matrix of 푓 evaluated at 푧ˆ푖(푡) and 푥0(푇 ) = 0.111
With respect to this perturbed system the output becomes112
푦푖(푡) = 퐶푥푖(푡) + 푦ˆ푖(푡)
and so the aim is to choose the 푢푖 such that113
퐶푥푖(푡푘푖) = 푦r(휏푖 + 푡푘푖)− 푦ˆ푖(푡푘푖) 푘푖 = 1푖, . . . ,푚푖
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for 푖 = 1, . . . , 푙 where 휏푖 = (푖− 1)푇 . Neglecting (for now) the nonlinearities,114
this corresponds to choosing 푢 = (푢1, . . . , 푢푙)
푇 such that:115
푀푢 =
⎛
⎜⎜⎜⎝
푀11 0 . . . 0
푀21 푀22 . . . 0
...
...
...
푀푙1 푀푙2 . . . 푀푙푙
⎞
⎟⎟⎟⎠
⎛
⎜⎜⎝
푢1
푢2
. . .
푢푙
⎞
⎟⎟⎠ = 푌d − 푌ˆ
where116
푀푖푗 =
⎛
⎜⎝
퐶휙푖(푡1푖 , 0)휙푖−1(푇, 0) . . . 휙푗(푇, 0)퐵
...
퐶휙푖(푡푚푖 , 0)휙푖−1(푇, 0) . . . 휙푗(푇, 0)퐵
⎞
⎟⎠
since (in the linear case)117
퐶푥푖(푡푘푖) = 퐶휙푖(푡푘푖 , 0) (푥푖−1(푇 ) + 퐵푢푖) .
The matrix 푀 ∈ ℝ푚×푙 is unlikely to be invertible and so the least squares118
solution is chosen:119
푢∗ =푀
†
(
푌d − 푌ˆ
)
,
where 푀 † is the pseudo-inverse of 푀 . Now considering the full nonlinear
system, let
풩푖푥(푡푘푖) = 퐶
∫ 푡푘푖
0
휙푖(푡푘푖 , 푠)푁푖(푠, 푥푖(푠)) d푠
+ 퐶휙푖(푡푘푖 , 0)
∫ 푇
0
휙푖−1(푇, 푠)푁푖−1(푠, 푥푖−1(푠)) d푠+ ⋅ ⋅ ⋅
+ 퐶휙푖(푡푘푖 , 0) . . . 휙2(푇, 0)
∫ 푇
0
휙1(푇, 푠)푁1(푠, 푥1(푠))d푠
and120
풩푥 = (풩1푥(푡11), . . . ,풩1푥(푡푁1), . . . ,풩푙푥(푡1푙), . . . ,풩푙푥(푡푁푙))푇 .
Then the linear approach suggests choosing 푢 such that:121
푢∗ =푀
†
(
푌d − 푌ˆ −풩 (푥)
)
,
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but, as in the last section this leads to an implicit equation for 푥 (the solution
on [0, 휏 ], 휏 = 푙×푇 , obtained by piecing together the 푥푖). Again, to overcome
this a ﬁxed-point is sought of the following operator, Ψ:
(Ψ푥) (휏푖 + 푡) = 휙푖(푡, 0)
[
푥푖−1(푇 ) + 퐵푀
†
푖
[
푌d − 푌ˆ −풩푥
]]
+
∫ 푡
0
휙푖(푡, 푠)푁(푠, 푥푖(푠)) d푠 (9)
where 푀 †푖 is the 푖
th row of 푀 †.122
If a ﬁxed-point of Ψ exists then the output corresponding to the ﬁxed123
point is given by:124
푌 = 푀푀 †
(
푌d − 푌ˆ −풩 (푥)
)
+풩 (푥) + 푌ˆ
= 푀푀 †푌d +
(
퐼 −푀푀 †) (푌ˆ +풩 (푥)) .
Hence the diﬀerence between the achieved proﬁle and the target proﬁle is125
given by:126
푌 − 푌d =
(
퐼 −푀푀 †) (푌ˆ − 푌d +풩 (푥)) ,
where the right-hand side is the orthogonal projection onto (ran푀)⊥. Thus127
it is seen that the reference proﬁle is matched on the range of 푀 .128
To illustrate the application of the ﬁxed point theorem to the problem129
of obtaining given points on a reference time-series, the single-dose case is130
considered ﬁrst by the following theorem:131
Theorem 3. Suppose that the following are satisﬁed:132
1. 푁(⋅, 푥(⋅)) ∈ 퐿푠(0, 푇 ;ℝ푛) whenever 푥(⋅) ∈ 퐿푟(0, 푇 ;ℝ푛) where 푟, 푠 ≥ 1133
are real numbers;134
2. 푁 : [0, 푇 ] × ℝ푛 −→ ℝ푛 is Lipschitz on the ball 퐵(푎) of radius 푎 about135
the origin in 퐿푟(0, 푇 ;ℝ푛):136
∥푁(⋅, 푧1(⋅))−푁(⋅, 푧2(⋅))∥푠 ≤ ℎ(∥푧1∥, ∥푧2∥)∥푧1 − 푧2∥푟
for 푧푖 ∈ 퐵(푎) and ℎ : ℝ+ × ℝ+ → ℝ+ is continuous, symmetric and137
ℎ(0, 0) = 0;138
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3. Let 푎 ≤ 푎 be such that139 [√
푚 ∥푀 †∥ ∥휙1∥ ∥퐵∥ ∥퐶∥+ 1
]
∥휙1∥푇˜퐾 = 퐾˜ < 1
where 퐾 = sup0≤푤,푣≤푎 ℎ(푤, 푣) and 푇˜ = 푇
(1+ 1
푟
− 1
푠
).140
If the target proﬁle, 푌d, is close to that corresponding to the initial dose, 푌ˆ ,141
in the sense that142
∥푌d − 푌ˆ ∥ ≤
푎
(
1− 퐾˜
)
푇 1/푟∥휙1∥ ∥퐵∥ ∥푀 †∥ (10)
then the operator Ψ in (9) (single-dose case) has a unique ﬁxed point.143
Proof. To see that Ψ is a contraction on the ball 퐵(푎) note that:144
∥Ψ푤 −Ψ푣∥푟 ≤ 푇˜∥휙1∥퐾∥푤 − 푣∥푟
+
√
푚푇˜∥푀 †∥∥휙1∥2∥퐵∥ ∥퐶∥퐾∥푤 − 푣∥푟
=
(√
푚 ∥푀 †∥ ∥휙1∥ ∥퐵∥ ∥퐶∥
+ 1
) ∥휙1∥푇˜퐾∥푤 − 푣∥푟
Let 푥0 = 0, 푥1 = Ψ푥0 = 휙1(⋅, 0)퐵푀 †
[
푌d − 푌ˆ푇
]
and 푆 be the ball145
푆 =
{
푥 ∈ 퐿푟(0, 푇 ;ℝ푛) : ∥푥− 푥1∥ ≤ 퐾˜
1− 퐾˜ ∥푥1∥푟
}
.
푆 is contained within the ball 퐵(푎) provided146 [
1 +
퐾˜
1− 퐾˜
]
∥휙1(⋅, 0)퐵푀 †
[
푌d − 푌ˆ푇
]
∥푟 ≤ 푎
which is guaranteed by (10). Applying Theorem 1 proves the required result.147
148
For the full multiple-dosing case the following result is obtained:149
Theorem 4. Suppose that the following are satisﬁed:150
1. 푁(⋅, 푥(⋅)) ∈ 퐿푠(0, 휏 ;ℝ푛) whenever 푥(⋅) ∈ 퐿푟(0, 휏 ;ℝ푛), 푟, 푠 ≥ 1 are real151
numbers;152
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2. 푁 : [0, 휏 ] × ℝ푛 −→ ℝ푛 is Lipschitz on the ball 퐵(푎) of radius 푎 about153
the origin in 퐿푟(0, 휏 ;ℝ푛):154
∥푁(⋅, 푧1(⋅))−푁(⋅, 푧2(⋅))∥푠 ≤ ℎ(∥푧1∥, ∥푧2∥)∥푧1 − 푧2∥푟
for 푧푖 ∈ 퐵푎 and ℎ : ℝ+ × ℝ+ → ℝ+ is continuous, symmetric and155
ℎ(0, 0) = 0.156
There exists an 푎 ≤ 푎 and a 퐾˜ such that if the target proﬁle, 푌d, is close to157
that corresponding to the initial dose, 푌ˆ , in the sense that158
∥푌d − 푌ˆ ∥ ≤
푎
(
1− 퐾˜
)
휏 1/푟∥휙∥ ∥퐵∥ ∥푀 †∥ (11)
then the operator Ψ in (9) has a unique ﬁxed point.159
Proof. First note that on the ball 퐵(푎):160
∥Ψ푤 −Ψ푣∥푟 ≤ (푘1 + 푘2퐾) ∥푤 − 푣∥푟
for suitable constants 푘1 and 푘2, where 퐾 = sup0≤푤,푣≤푎 ℎ(푤, 푣). Therefore,161
choosing 푎 ≤ 푎 such that162
푘1 + 푘2퐾 = 퐾˜ < 1
it is seen that Ψ is a contraction on 퐵(푎).163
Let 푤 = 0, 푣 = Ψ푤 so that164
푣(휏푖 + 푡) = 휙푖(푡, 0)퐵푀
†
푖
[
푌d − 푌ˆ
]
and 푆 be the ball165
푆 =
{
푥 ∈ 퐿푟(0, 휏 ;ℝ푛) : ∥푥− 푣∥ ≤ 퐾˜
1− 퐾˜ ∥푣∥푟
}
.
푆 is contained within the ball 퐵(푎) provided (11) is satisﬁed. Applying166
Theorem 1 proves the required result.167
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4. Example168
To illustrate the theory of the previous two sections the results are applied169
to a model for the in vitro kinetics of the anti-cancer agent topotecan [1].170
The model describes the distribution and activity of the drug when added to171
a medium containing human cancer cells (data from the MCF-7 breast cancer172
cell line was used by Evans et al. [1] in estimating the model parameters).173
The concentration of pharmacologically active drug is denoted by 퐿 while174
the corresponding concentration for the inactive form is denoted by 퐻. A175
schematic of the model is shown in Figure 1.176
To allow for mixing in the physical medium (as seen in the experimental177
data) it is divided into two pools: the medium pool (denoted by a subscript178
m), which represents the majority of the physical medium and is the pool into179
which the drug is added; and an extracellular pool (denoted by a subscript180
e), which represents the part of the physical medium in which the cells are181
located. Therefore active drug enters the system via the medium pool (where182
reversible hydrolysis to the inactive form takes place) and can then mix with183
the extracellular pool (with reversible ﬁrst order rate processes). Reversible184
hydrolysis also occurs in the extracellular pool.185
From the extracellular pool active drug diﬀuses across the cell membrane186
into the cytoplasm (denoted by a subscript c) and this process is ﬁrst order187
in both directions. Reversible hydrolysis of the active form of the drug also188
occurs in the cytoplasm. Only active drug in the cytoplasm is assumed to189
enter the nucleus (denoted by a subscript n), where it binds to the target.190
The concentration of active drug bound to DNA, represented in the model191
by 퐿푛, can therefore be related to the eﬀect of the drug. Evans et al. [1] used192
the AUC for 퐿푛 over the ﬁrst hour following administration as a surrogate193
for drug eﬀect. More recently, Chappell et al. [5] directly coupled the kinetic194
model, using 퐿푛, to a cell cycle model in order to model the eﬀect of a dose195
on the cell cycle.196
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The model equations are as follows:
퐿˙푚 = −(푘표푚 + 푘푚푖)퐿푚 + 푘푐푚퐻푚 + 푘푚표푣0퐿푒
퐻˙푚 = 푘표푚퐿푚 − (푘푐푚 + 푘푚푖)퐻푚 + 푘푚표푣0퐻푒
퐿˙푒 =
푘푚푖
푣0
퐿푚 − (푘푚표 + 푘표푚 + 푘푖)퐿푒 + 푘푐푚퐻푒 + 푘푒
푣1
퐿푐
퐻˙푒 =
푘푚푖
푣0
퐻푚 + 푘표푚퐿푒 − (푘푐푚 + 푘푚표)퐻푒
퐿˙푐 = 푘푖푣1퐿푒 − (푘푒 + 푘표푐)퐿푐 + 푘푐푐퐻푐 + 푘푑푙푣2퐿푛 − 푘푏(퐵푇 − 퐿푛)퐿푐
퐻˙푐 = 푘표푐퐿푐 − 푘푐푐퐻푐 + 푘푑ℎ푣2퐿푛
퐿˙푛 =
푘푏
푣2
(퐵푇 − 퐿푛)퐿푐 − (푘푑푙 + 푘푑ℎ)퐿푛
where 푣0 = 푉푒/푉푚 is the ratio of the volumes of the extracellular pool (푉푒) and197
medium pool (푉푚), 푣1 = 푉푒/푉푐 is the ratio of the volumes of the extracellular198
pool and cytoplasm (푉푐), and 푣2 = 푉푛/푉푐 is the ratio of the volumes of the199
nucleus (푉푛) and cytoplasm. The corresponding initial conditions for the200
model are:201
퐿푚(0) = (1 + 푣0)푑, 퐻푚(0) = 퐿푒(0) = 퐻푒(0) = 퐿푐(0) = 퐻푐(0) = 퐿푛(0) = 0.
The problem is to choose the dose 푑.202
4.1. AUC: Single dose203
The ﬁrst problem considered is to achieve an AUC for 퐿푛, over a one204
hour exposure, of 43.2 mol⋅s/m3 (12 휇M⋅h), which is expected to require a205
dose greater than 10 mmol/m3 (휇M) [1]. Using the approach of Section 2 the206
known initial condition 푧0 in (1) is the zero vector, since no drug is present207
prior to the start of the experiment; the matrix deﬁning the structure of the208
input dose, 퐵, is given by209
퐵 =
(
(푣0 + 1) 0 0 0 0 0 0
)푇
.
Once an initial estimate, 푑ˆ, is made for the dose and the perturbed system210
about the resulting trajectory, 푧ˆ(⋅), obtained, the proof of Theorem 2 provides211
a constructive means for determining the ﬁxed-point of Ψ deﬁned in (4). Once212
this ﬁxed-point has been determined then (3) is used to determine 푢∗ and213
the required dose is 푑ˆ+ 푢∗.214
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For initial estimates for the dose, 푑ˆ, up to 40 mmol/m3 (휇M) the required215
dose can be found, using this approach, to be 10.53 mmol/m3 (휇M), which216
gives a peak concentration of bound drug (퐿푛) of 13.55 mmol/m
3 (휇M).217
A plot of the resulting nuclear bound drug is shown in Figure 2. For initial218
estimates less than that required for the prescribed AUC, the approach results219
in the required dose. As the initial estimate for the dose exceeds that required220
convergence becomes an issue since the value of푚푇 decays exponentially with221
the estimate used. In particular, the weighted error for the initial estimate,222
∥푦d− 푦ˆ푇∥/푚푇 , grows in a parabolic fashion ensuring that (5) no longer holds223
(see Figure 3).224
4.2. AUC: Multiple doses225
Suppose that it is necessary, in the previous problem, to limit the peak226
concentration of bound drug (퐿푛) or to limit the administered dose 푑 at any227
instant. A straightforward way to do this is to split the dose into 푁 multiple228
doses, 푑푖, given at equal time points, 푡푖 = (푖 − 1)푇/푁 , throughout the full229
dosing period 푇 (where 푇 = 1 h in this example). The approach taken230
in the previous section can then be applied on each of the dosing intervals231
([푡푖, 푡푖+1) for 푖 = 1, . . . , 푁) as a single dose AUC problem. The problem of232
determining doses to give a certain AUC across the whole of the time interval233
[0, 푇 ] then becomes 푁 separate single-dose problems such that the total sum234
is the required AUC.235
For 푁 = 2 two doses are applied, one at 푡 = 0 and the other at 푡 = 30 min-236
utes, and the problem is split into two single-dose AUC problems correspond-237
ing to these doses. The second single-dose AUC problem, on the last 30 min-238
utes of exposure, uses the ﬁnal state of the ﬁrst problem (i.e., at 30 minutes)239
as the known initial condition. It therefore only remains to split the target240
AUC into the sum of two values that are to be achieved on the two dosing241
intervals. The limiting factor in dividing the AUC is the value for the ﬁrst242
interval, since prior to the ﬁrst dose no drug is present in the system and so243
the target concentration, 퐿푛, has to build up. However, if the value chosen244
is too small the dose required for the second interval might be too high. If245
the aim of the dosing strategy is to achieve a total AUC of 43.2 mol⋅s/m3246
(12 휇M⋅h), but limit 퐿푛 to less than 13 mmol/m3 (휇M) then the AUC can be247
split into 20.34 mol⋅s/m3 (5.65휇M⋅h) and 22.86 mol⋅s/m3 (6.35휇M⋅h). The248
ﬁrst of these values is chosen to be the maximum possible while limiting249
the peak bound concentration to less than 13 mmol/m3 (휇M). The neces-250
sary doses for these two single-dose AUC problems are 9.95 mmol/m3 (휇M)251
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and 1.17 mmol/m3 (휇M), respectively. On the two time intervals the peak252
concentrations of bound drug are 12.91 mmol/m3 (휇M) and 13.01 mmol/m3253
(휇M), respectively. A plot of the resulting nuclear bound drug is shown in254
Figure 2 where the proﬁle is seen to give a lower peak than the single dose255
case and maintains a more constant level.256
Extending to four doses given at 0, 15, 30, and 45 minutes, the AUC257
can be split into 8.46, 11.52, 11.52, and 11.7 mol⋅s/m3 (2.35, 3.2, 3.2, and258
3.25 휇M⋅h). With more doses there is greater ﬂexibility in splitting the259
required AUC, though the value than can be achieved on the ﬁrst interval260
is limited since no drug is present before administration. The values that261
the target AUC are divided into are chosen to ﬂatten the time-series plot of262
bound nuclear (target) drug. The corresponding doses are 9.29, 1.05, 0.55,263
and 0.79 mmol/m3 (휇M), and the peak concentrations of bound drug are264
12.17, 12.98, 12.91, and 13.11 mmol/m3 (휇M). A plot of the resulting nuclear265
bound drug is shown in Figure 2 where the proﬁle is seen to maintain a much266
more constant level than the single or double dose cases.267
It should be noted that this method does not exploit the fact that at the268
end of any given dosing period there is drug stored within the compartments269
and that the amount of drug present is dependent on all of the previous doses.270
Although an approach based on that taken with the time-series problem in271
Section 3 would exploit this dependence, it would not utilise the fact that272
on any given dosing period there exists a dose that gives the required AUC273
exactly.274
From Figure 2 it is seen that a potentially limiting factor is the initial275
rise in drug bound to the target. This initial rise is dependent on the size276
of the ﬁrst dose, which then aﬀects subsequent doses. For example, notice277
that in the case of four equally spaced doses the bound concentration does278
not approach the constant level until the second dose, whereas for the single279
and double dose cases this happens for the ﬁrst dose, though there is corre-280
sponding over-shoot of the average level. The eﬀect of these issues is that the281
ﬁrst dose might be constrained by a maximum target level (in this example282
bound active drug), which then limits the initial slope and hence the AUC283
that can be achieved on the ﬁrst dosing interval. Subsequent dosing inter-284
vals are then limited in turn as a result. To overcome these points the AUC285
problem can be reformulated in terms of achieving a particular time-series,286
such as a constant level, that has the required AUC.287
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4.3. Time-series: Reconstruction of dose288
To illustrate the theory of Section 3 a theoretical example is considered289
ﬁrst in which a time-series corresponding to a particular dosing regime is290
used to try to ﬁnd the original dosing schedule. More precisely, the following291
sequence of doses is applied every 15 minutes for a total duration of one hour:292
2, 5, 2, and 1 mmol/m3 (휇M). The time series is sampled at times 5, 10, 15,293
20, 25, 30, 40, and 50 minutes after the ﬁrst dose.294
Starting with an initial guess of 1, 0, 0, and 0 mmol/m3 (휇M) the method295
ﬁnds the original dosing scheme. Similarly, if the scheme were grossly over-296
estimated, say with an initial guess of 10, 10, 10, and 10 mmol/m3 (휇M),297
the method ﬁnds the original dosing scheme. The desired sample points are298
plotted in Figure 4 together with the time series for the nuclear bound drug,299
퐿푛. Unsurprisingly, there is good correspondence between the time-series300
proﬁle and the target one.301
4.4. Time-series: Modifying existing series302
The target proﬁle from the previous section is modiﬁed by reducing all303
points to 10% of their previous values and the method run again. This sce-304
nario represents the case where the proﬁle of an existing dosing scheme needs305
to be reduced. The dosing scheme in this case is given by 0.20, 0.45, 0.16, and306
0.08 mmol/m3 (휇M). The resulting proﬁle for bound active drug is plotted307
in Figure 5, together with the target points. There is good correspondence308
between the time series for the dosing scheme and the target.309
Conversely, the target proﬁle from the previous section is doubled and310
the method run again. In this case the dosing scheme returned is given by311
4.09, 11.50, 5.30, and 2.55 mmol/m3 (휇M). The resulting proﬁle for bound312
active drug is plotted in Figure 6, together with the target points. Again,313
there is good correspondence between the time series for the dosing scheme314
and the target.315
It was seen in Section 3 that the method for ﬁnding the required dose316
is guaranteed to achieve the required proﬁle on the range of the matrix317
푀 , provided the proﬁle corresponding to the initial estimate for the dose318
is close enough to the target. The aim in modifying the series arising from a319
given dose is to minimise the orthogonal projection of the target proﬁle onto320
(ran푀)⊥ and therefore enabling a good correspondence between actual and321
target series to be achieved.322
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4.5. Time-series: Constant proﬁle323
While considering the problem of obtaining a given AUC from multiple324
doses it was found that the problem could be reformulated in terms of repro-325
ducing a constant, or piecewise constant, time-series. First the problem of326
achieving a target dose consisting of a constant 10 mmol/m3 (휇M) with four327
doses 15 minutes apart is considered. The dosing scheme obtained is 7.67,328
0.08, 0.54, and 0.33 mmol/m3 (휇M) and the resulting time series for bound329
nuclear active drug is shown in Figure 7. As was noted for the multiple-dose330
AUC problem the initial slope of the bound drug curve is determined by331
the initial dose, which is inﬂuenced for the time-series problem by the ﬁrst332
target point, 푦r(푡1). This example highlights a limitation of the method for333
ﬁnding the doses in that the doses should be constrained to be non-negative.334
If the ﬁrst time point is too close to zero the resulting ﬁrst dose results in335
large over-shoot before the second dose is delivered and so a negative value is336
obtained for the second dose. By choosing a sampling of every 10 minutes up337
to 30 minutes, and then every 5 minutes avoids this problem, but this is not338
ideal. From Figure 7 it is seen that there is good correspondence between339
the achieved proﬁle and the target one.340
Considering the graph of the bound drug time series in Figure 7 the ap-341
proximate AUC for the last 50 minutes is 30 mol⋅s/m3 (8.33 휇M⋅h). The AUC342
for the ﬁrst 10 minutes is between 3 mol⋅s/m3 (0.83 휇M⋅h) and 6 mol⋅s/m3343
(1.67 휇M⋅h), giving a total AUC of between 33 mol⋅s/m3 (9.17 휇M⋅h) and344
36 mol⋅s/m3 (10 휇M⋅h). Modifying the target dose to a constant 12.5 mmol/m3345
(휇M) (with four doses 15 minutes apart is considered) yields a dosing scheme346
of 9.87, 0.13, 0.70, and 0.42 mmol/m3 (휇M) and the resulting time series for347
bound nuclear active drug is shown in Figure 8. For this dosing scheme the348
approximate AUC is between 41.25 mol⋅s/m3 (11.5 휇M⋅h) and 45 mol⋅s/m3349
(12.5 휇M⋅h). The concentration of bound active drug is limited to a max-350
imum value of 12.85 mmol/m3 (휇M). Compared with the dosing schedule351
to achieve an AUC of 43.2 mol⋅s/m3 (12 휇M⋅h) it is seen that the dose has352
been successfully limited to below 13 mmol/m3 (휇M) and yet the target353
AUC has been approximately achieved; the actual AUC for this example is354
42.77 mol⋅s/m3 (11.88 휇M⋅h).355
5. Conclusions356
A ﬁxed point approach has been employed to determine dosing schemes357
that determine arbitrary area-under-curve for desired model species, or to358
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determine schemes that give rise to particular time series points for the de-359
sired model species. The approach is a model based one and so applicability360
is dependent on the validation of the proposed model.361
Applying the approach for arbitrarily setting the area-under-curve mul-362
tiple times can give greater ﬂexibility in avoiding large peak values or pro-363
hibitively large doses. However, a draw-back of this computationally easier364
approach is that dependence between doses in a scheme is ignored.365
The approach to reproduce time series data works well in the case of366
reconstructing an unknown dose, or modifying an existing proﬁle. For an367
arbitrary proﬁle the approach does not guarantee to determine a dose that368
produces it. Indeed, such a proﬁle may be outside the range of feasible369
proﬁles.370
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Figure 1: Schematic of the mathematical model developed by Evans et al. [1] to investigate
the uptake kinetics of TPT in a culture medium containing human breast cells (MCF-7
cell line) in suspension.
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Figure 2: Plots of bound active drug, 퐿푛(푡), against time with total area-under-curve of
43.2 mol⋅s/m3 (12 휇M⋅h). Plots correspond to single, double and quadruple doses.
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Figure 3: Plot of weighted initial error, 퐸 = ∥푦d − 푦ˆ푇 ∥/푚푇 , against initial dose estimate,
푑ˆ, for the single-dose AUC problem.
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Figure 4: Plot of bound active drug, 퐿푛(푡), against time with target time series points
(square boxes) when reconstructing an unknown dosing scheme.
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Figure 5: Plot of bound active drug, 퐿푛(푡), against time with target time series points
(square boxes) when previous target is reduced to 10% of its original value.
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Figure 6: Plot of bound active drug, 퐿푛(푡), against time with target time series points
(square boxes) when target from Figure 4 is double its original level.
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Figure 7: Plot of bound active drug, 퐿푛(푡), against time with a constant (10 휇M) target
time series points (square boxes).
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Figure 8: Plot of bound active drug, 퐿푛(푡), against time with a constant target (12.5 휇M)
time series points (square boxes).
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